Roche setback in Delhi HC paves way for cheaper spinal muscular atrophy (SMA) drug

The Delhi High Court has dismissed Roche’s appeal, allowing Natco to launch a generic version of Risdiplam for spinal muscular atrophy. This decision prioritizes public health and patient access over monopolistic practices, potentially making the life-saving drug significantly more affordable for Indian patients. Roche is considering further appeals.